Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function

Hypertension

Volumn 52, Issue 5, 2008, Pages 967-973

  Rentzsch, Brit ^a,b   Todiras, Mihail ^a   Iliescu, Radu ^a   Popova, Elena ^a   Campos, Luciana A ^a   Oliveira, Marilene L ^c   Baltatu, Ovidiu C ^a   Santos, Robson A ^c   Bader, Michael ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

ACE2; Angiotensin ii; Angiotensin (1 7); Endothelial function; SHRSP

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; ACETYLCHOLINE; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; NITROPRUSSIDE SODIUM; PEPTIDE FRAGMENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPERTENSION; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC RAT; VASCULAR SMOOTH MUSCLE; ANIMAL; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; VASODILATOR AGENTS;

EID: 55949126600     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.114322     Document Type: Article

References (46)

1. Hall JE. Control of blood pressure by the renin-angiotensin-aldosterone system. Clin Cardiol. 1991;14:IV6-IV21.
2. Santos RA, Simoes e Silva AC, Marie C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
3. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 1996;28: 104-108.
4. le Tran Y, Forster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol. 1997;30:676-682.
5. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802.
6. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 2003;284:H1985-H1894.
7. Mahon JM, Carr RD, Nicol AK, Henderson IW. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens. 1994;12: 1377-1381.
8. Brosnihan KB, Li P, Ferrario C. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27: 523-528.
9. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400.
10. Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther. 1998;284:388-398.
11. Fernandas L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Catelli De Carvalho MH. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 2001;37:703-709.
12. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension. 2005;46:937-942.
13. Soares de Moura R, Resende AC, Emiliano AF, Tano T, Mendes-Ribeiro AC, Correia ML, de Carvalho LC. The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 2004;141:860-866.
14. Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, Siems WE, Walther T. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides. 2005;26:1270-1277.
15. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin- converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48:914-920.
16. Biased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension. 2006;47:1010-1017.
17. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, Burrell LM, Smith AI. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol. 2008;93: 685-693.
18. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87: E1-E9.
19. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
20. Rivière G, Michaud A, Breton C, VanCamp G, Laborie C, Enache M, Lesage J, Deloof S, Corvol P, Vieau D. Angiotensin-Converting Enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition- programmed hypertension in the adult rat. Hypertension. 2005;46:1169-1174.
21. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension. 2004;43:1120-1125.
22. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
23. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther. 2001; 298:879-885.
24. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
25. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab. 2002;4:224-238.
26. Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol. 1999;31:39-49.
27. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37.
28. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130: 963-974.
29. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;106: 3073-3078.
30. Popova E, Krivokharchenko A, Ganten D, Bader M. Efficiency of transgenic rat production is independent of transgene-construct and overnight embryo culture. Theriogenology. 2004;61:1441-1453.
31. Akyürek LM, Yang ZY, Aoki K, San H, Nabel GJ, Parmacek MS, Nabel EG. SM22alpha promoter targets gene expression to vascular smooth muscle cells in vitro and in vivo. Mol Med. 2000;6:983-991.
32. Graham D, Hamilton C, Beattie E, Spiers A, Dominiczak AF. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. J Hypertens. 2004;22: 329-337.
33. Shimamura T, Nakajima M, Iwasaki T, Hayasaki Y, Yonetani Y, Iwaki K. Analysis of circadian blood pressure rhythm and target-organ damage in stroke-prone spontaneously hypertensive rats. J Hypertens. 1999;17: 211-220.
34. Huentelman MJ, Zubcevic J, Hernández Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004;44:903-906.
35. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13:93-101.
36. Lieb W, Graf J, Götz A, König IR, Mayer B, Fischer M, Stritzke J, Hengstenberg C, Holmer SR, During A, Löwel H, Schunkert H, Erdmann J. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med. 2006;84:88-96.
37. Yang W, Huang W, Su S, Li B, Zhao W, Chen S, Gu D. Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci (Lond). 2006;111:333-340.
38. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185-192.
39. Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol. 2002;80: 369-374.
40. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, lives M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-440.
41. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G, Lazartigues E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated presser and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res. 2008;102:729-736.
42. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL, Bader M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics. 2004;17:292-299.
43. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ. Impairment of in vitro and in vivo heart function in angiotensin-(l-7) receptor MAS knockout mice. Hypertension. 2006;47: 996-1002.
44. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;292:H3019-H3024.
45. Peiró C, Vallejo S, Gembardt F, Azcutia V, Heringer-Walther S, Rodríguez-Mañas L, Schultheiss HP, Sánchez-Ferrer CF, Walther T. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens. 2007;25:2421-2425.
46. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS genedeleted mice. Hypertension. 2008;51:574-580.